Overview
| PharmGKB Accession Id: | PA452604 |
|---|
ATC Therapeutic Category
- X.01:xenobiotics
Curated Annotations (
)
-
rs58597806
at chr2:234246085
in
UGT1A10,
UGT1A7,
UGT1A8,
UGT1A9
A study in 100 healthy Japanese volunteers showed that carriers of D256N may be at risk of suffering adverse effects of propofol and other substrates that are primarily metabolized by UGT1A9. In in vitro analyses the K(m) of wild-type and D256N for propofol glucuronidation were 111.2 and 43.6 microM, respectively. The V(max) of D256N was 8.1% and the efficiencies (V(max)/K(m)) was 19.1% of the wild-type. The V(max) value of D256N variant for mycophenolic acid was only 9.5% of the wild-type.- Variant Name:
- UGT1A9: D256N
- Related Drugs:
- propofol, xenobiotics
- Evidence:
-
PMID:18816295
The following genes are in curated knowledge about this drug.
Primary phenotype data has been submitted and is available
Primary genotype data has been submitted and is available
Literature annotations available
A list of non-curated publications that mention this drug along with other genes is available.
A list of non-curated publications that mention this drug along with other drugs is available.
Curated Information
The following diseases are in curated knowledge about this drug.
Non-Curated Information
A list of non-curated publications that mention this drug along with other diseases is available.
Common Searches
Search PubMed
Search Medline Plus
Search PubChem
Search CTD
Non-Curated Publications
A list of non-curated publications that mention this drug is available.